Tag: FDA approval tafasitamab-cxix

Home / FDA approval tafasitamab-cxix

Categories

Tafasitamab-cxix is approved by the USFDA for relapsed or refractory follicular lymphoma

On June 18, 2025, the Food and Drug Administration sanctioned tafasitamab-cxix (Monjuvi, Incyte Corporation) in conjunction with lenalidomide and rituximab for adults with relapsed or refractory folli...
fda-approval-tafasitamab-cxix

Scan the code